Processing...
Clinical Trials for Head And Neck Cancer
Search
Search
There are 201 active trials for advanced/metastatic head and neck cancer.
Click on a trial to see more information.
201 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with metastatic or unresectable solid tumors harboring AKT/PI3K/PTEN pathway alterations (excluding concurrent EGFR/KRAS/NRAS/HRAS/BRAF drivers) receive the investigational AKT-pathway inhibitor TER-2013 as monotherapy (expansion in ovarian/cervical/SCCHN/lung/esophageal and endometrial cancers) or with fulvestrant for HR+/HER2- breast cancer previously treated with an aromatase inhibitor. Prior AKT/PI3K/PTEN inhibitors (and prior SERD/mTOR in combo expansion) are excluded; requires ECOG 0–1 and adequate organ function.
ClinicalTrials.gov ID: NCT07109726
TrialFetch AI summary: Adults with metastatic melanoma, colorectal cancer, pancreatic ductal adenocarcinoma, or head and neck squamous cell carcinoma harboring MAPK-pathway mutations and no suitable standard options receive oral IPN01194 monotherapy, an ERK1/2 (MAPK1/3) inhibitor targeting the terminal RAS–RAF–MEK–ERK pathway. Dose-escalation identifies two doses, followed by randomized expansion in a single tumor type to assess activity.
ClinicalTrials.gov ID: NCT06305247
TrialFetch AI summary: Adults <70 with metastatic gastrointestinal or peritoneal tumors (esophageal, gastric, colorectal, liver, pancreatic) refractory to standard therapy, with at least one lesion amenable to intratumoral injection. Single intratumoral dose of vvDD-hIL2-2-RG-1, an oncolytic vaccinia virus (double-deleted TK/VGF) engineered to express membrane-tethered IL-2 to promote localized T-cell activation and oncolysis; no combination therapy in this first-in-human, single-dose escalation.
ClinicalTrials.gov ID: NCT07001592
TrialFetch AI summary: Adults with metastatic or unresectable HER2‑negative adenocarcinoma of the esophagus/GEJ/stomach (no prior metastatic therapy; ECOG 0–2) receive an alternating doublet sFOLFOXIRI schedule: mFOLFOX6 on odd cycles and FOLFIRI on even cycles every 2 weeks. Optional nivolumab (PD‑1 inhibitor) may be added per label to enhance antitumor activity.
ClinicalTrials.gov ID: NCT05332002
TrialFetch AI summary: Adults with locally advanced/metastatic solid tumors (ECOG 0–1) who have progressed on prior therapy and lack standard options receive SPX‑303 monotherapy, a first‑in‑class bispecific antibody targeting LILRB2 (ILT4) on myeloid cells and PD‑L1, given IV every 3 weeks. Excludes active/unstable CNS disease and prior ILT2/ILT4/HLA‑G–targeted therapy; allows well-controlled HIV.
ClinicalTrials.gov ID: NCT06259552
TrialFetch AI summary: Adults with untreated recurrent/metastatic HNSCC (non‑nasopharyngeal) eligible for pembrolizumab are randomized to pembrolizumab alone versus pembrolizumab plus BI 770371 (anti‑SIRPα blocking the CD47–SIRPα “don’t‑eat‑me” axis) with or without cetuximab (anti‑EGFR). Prior definitive therapy is allowed if >6 months from progression; requires measurable disease and tumor tissue, and excludes prior PD‑(L)1 or SIRPα/CD47 agents and active brain metastases.
ClinicalTrials.gov ID: NCT06806852
TrialFetch AI summary: Adults with recurrent/metastatic, incurable HNSCC (oral cavity, oropharynx, hypopharynx, larynx, or cervical node with occult primary) who are chemo‑naïve in the R/M setting and not candidates for infusional 5‑FU receive pembrolizumab (anti–PD‑1) plus weekly carboplatin/paclitaxel for six cycles, then pembrolizumab maintenance. Key exclusions include untreated symptomatic CNS mets, active autoimmune disease needing immunosuppression, prior severe hypersensitivity to carboplatin/paclitaxel, and significant uncontrolled comorbidities.
ClinicalTrials.gov ID: NCT04858269
TrialFetch AI summary: Adults with advanced/metastatic urothelial carcinoma or squamous cell carcinomas (lung, esophagus, cutaneous, head/neck, anogenital) after standard therapies receive single‑agent EVOLVE104, a trispecific T‑cell engager targeting ULBP2/5/6 with CD3 binding and CD2 costimulation. Open‑label dose escalation and expansion assess safety, PK, and preliminary efficacy, with treatment continued until progression or intolerance.
ClinicalTrials.gov ID: NCT07217171
TrialFetch AI summary: Adults with advanced/metastatic solid tumors lacking effective standard options (broad basket with prioritized cohorts such as CRC, SCLC, HNSCC, NSCLC, pancreatic, and bladder; some genomically enriched) receive oral single‑agent CP-383 in dose escalation and tumor‑specific expansions. CP-383 is a first‑in‑class small molecule designed to modulate lipid‑binding pockets on oncogenic proteins (exact target undisclosed).
ClinicalTrials.gov ID: NCT07030257
TrialFetch AI summary: Adults with advanced/metastatic urothelial/bladder cancer, NSCLC, HNSCC, esophageal cancer, or pancreatic adenocarcinoma (ECOG 0–1) receive PF-08046876, an ITGB6-targeted antibody–drug conjugate delivering a topoisomerase I payload, as IV monotherapy after prior standard therapy (≤2 prior lines in Part 2). Dose escalation/optimization and tumor-specific expansions assess safety, PK, and preliminary activity; excludes prior camptothecin/topo I ADC exposure and significant GI or pulmonary comorbidities.
ClinicalTrials.gov ID: NCT07090499